Graft Rejection Clinical Trials

9 recruitingLast updated: June 18, 2026

There are 9 actively recruiting graft rejection clinical trials across 7 countries. Studies span Not Applicable, Phase 2, Phase 3, Phase 4. Top locations include Nashville, Tennessee, United States, Falls Church, Virginia, United States, Barcelona, Spain. Updated daily from ClinicalTrials.gov.


Graft Rejection Trials at a Glance

9 actively recruiting trials for graft rejection are listed on ClinicalTrialsFinder across 6 cities in 7 countries. The largest study group is Not Applicable with 1 trial, with the heaviest enrollment activity in Nashville, Falls Church, and Barcelona. Lead sponsors running graft rejection studies include Inova Health Care Services, Hospital Universitari Vall d'Hebron Research Institute, and Centre Hospitalier Universitaire de Besancon.

Browse graft rejection trials by phase

Treatments under study

About Graft Rejection Clinical Trials

Looking for clinical trials for Graft Rejection? There are currently 6 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Graft Rejection trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Graft Rejection clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 19 of 9 trials

Recruiting

Long-term Evaluation and Follow-up Care of Patients Treated With Stem Cell Transplants

Graft vs Host DiseaseGraft-versus-leukemiaGraft Rejection
National Heart, Lung, and Blood Institute (NHLBI)1,000 enrolled1 locationNCT00106925
Recruiting
Phase 2

[68Ga]Ga-PentixaFor PET/CT in Acute Myocardial Inflammation

Myocarditis Due to DrugCardiac SarcoidosisAcute Cellular Graft Rejection
John O. Prior69 enrolled1 locationNCT05499637
Recruiting

OPtimal Adult Heart Transplant Immunosuppression With MicroRNA Levels

Cardiac FailureGraft Rejection
Inova Health Care Services250 enrolled7 locationsNCT06939751
Recruiting

Optimal Pediatric Heart Transplant Immunosuppression With MicroRNAs

Cardiac FailureGraft Rejection
Inova Health Care Services150 enrolled7 locationsNCT06532890
Recruiting

ZeroHeart Biopsy - Prediction of Deceased Donor Heart Transplant Performance From Organ Donors Using Pre-Transplant Biopsies - A Pilot Study

Myocardial InjuryOrgan PreservationHeart Transplantation+3 more
Medical University of Vienna50 enrolled1 locationNCT06982404
Recruiting
Not Applicable

MORPHEE : Mechanisms of Cell Death Induced by Extracorporeal Photochemotherapy

Graft vs Host DiseaseGraft RejectionCutaneous T Cell Lymphoma
Centre Hospitalier Universitaire de Besancon20 enrolled1 locationNCT05333367
Recruiting
Phase 4

Study to Compare the Outcome of Receiving Continued Immunosuppression Versus Stopping Immunosuppression at 6 Months to Safely Prevent Human Leukocyte Antigen (HLA) Sensitization in Patients With Late Renal Graft Failure

Graft RejectionGraft FailureRenal Failure Chronic+2 more
Hospital Universitari Vall d'Hebron Research Institute202 enrolled1 locationNCT06676696
Recruiting

Diagnosis of Graft Pathology by TruGraf

Acute Graft Rejection
University Health Network, Toronto471 enrolled1 locationNCT06557564
Recruiting
Phase 3

Budesonide versus prednisolone after liver transplantation: a phase 3, open label, non-inferiority randomised controlled trial

Allograft rejection
Austin Health100 enrolled1 locationACTRN12623000340639